论文部分内容阅读
目的观察阿司匹林联合双嘧达莫预防老年非瓣膜性心房颤动(房颤)患者发生血栓栓塞事件的有效性与安全性。方法将确诊的老年非瓣膜性房颤患者195例,随机分为2组。阿司匹林联合双嘧达莫组(联合治疗组)给予阿司匹林(100 mg,1次/d)+双嘧达莫(100 mg,3次/d);阿司匹林组给予(100 mg,1次/d)。观察2组血栓栓塞事件、出血及其他不良反应的发生率。结果随访时间12～28(20±7)个月。2组均无严重出血。联合治疗组血栓栓塞事件的发生率明显低于阿司匹林组(8.3%比18.2%,P<0.05),轻微出血及其他不良反应总的发生率差异无统计学意义(14.6%比8.1%,P>0.05)。结论阿司匹林联合双嘧达莫预防老年非瓣膜性房颤血栓栓塞事件安全有效。
Objective To investigate the efficacy and safety of aspirin plus dipyridamole in preventing thromboembolism in elderly patients with nonvalvular atrial fibrillation (AF). Methods A total of 195 elderly patients with non-valvular atrial fibrillation were randomly divided into two groups. Aspirin and dipyridamole were given aspirin 100 mg once daily plus dipyridamole 100 mg thrice daily and aspirin 100 mg once daily. . The incidence of thromboembolism, bleeding and other adverse reactions in the two groups were observed. Results The follow-up time ranged from 12 to 28 (20 ± 7) months. No severe bleeding in 2 groups. The incidence of thromboembolism in the combination therapy group was significantly lower than that in the aspirin group (8.3% vs 18.2%, P <0.05), and there was no significant difference in the overall incidence of mild bleeding and other adverse reactions (14.6% vs 8.1%, P> 0.05). Conclusions Aspirin combined with dipyridamole is safe and effective in preventing non-valvular atrial fibrillation thromboembolism.